INCY

Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company founded in 1991 and headquartered in Wilmington, Delaware. The company went public in 1993 and has evolved from a genomics research company into a fully integrated biopharmaceutical enterprise focused on discovering, developing, and commercializing innovative therapeutics. Incyte operates primarily in the United States and internationally, with a strong presence in oncology, hematology, and dermatology markets. The company has successfully transitioned from a research-focused organization to one with multiple marketed products generating substantial revenue, while maintaining a robust pipeline of experimental therapies across various therapeutic areas.